Roberta Minari

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Melissa Bersanelli, Roberta Minari, Paola Bordi et al. · Journal of Thoracic Oncology · 2016 · 166 citations · Full text

Medicine, Medicinal Chemistry, Oncology +15

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Giulia Mazzaschi, Roberta Minari, Alessandra Zecca et al. · Lung Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Roberta Minari, Paola Bordi, Marzia Del Re et al. · Lung Cancer · 2017 · 108 citations

Medicine, Pathology, Pharmacotherapy +11

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib

Donatella Callegari, Kara E. Ranaghan, Christopher Woods et al. · Chemical Science · 2018 · 90 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Silvia La Monica, Daniele Cretella, Mara Bonelli et al. · Journal of Experimental & Clinical Cancer Research · 2017 · 89 citations · Full text

Medicine, Oncology, Pharmacology +16